Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00998582 · ClinicalTrials.gov registry record · Phase 4
Artery Elasticity After Switch From Epzicom to Truvada
A Phase 4 study, sponsored by Hennepin Healthcare Research Institute.
- Terminated
- Registry status
- Phase 4
- Development phase
- 27
- Enrollment target
NCT00998582 is a Phase 4 study that was terminated before completion, run by Hennepin Healthcare Research Institute. The registered enrollment target is 27 participants.
The verdict
NCT00998582, a Phase 4 study, was terminated before completion, sponsored by Hennepin Healthcare Research Institute.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 27 participants
- Enrollment target
Study Summary
Recent research as suggested that use of the HIV medication abacavir (Ziagen, or co-formulated with lamivudine as Epzicom) may increase risk for heart disease, though findings from multiple studies have been inconsistent. This pilot study will examine vascular function, a marker of heart disease risk, among patients taking abacavir as part of their HIV medications and are then randomized to: 1) switch to tenofovir, another HIV medication, or 2) continue to take abacavir.
Interventions
- DRUG Tenofovir disoproxil
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2009-10 |
| Est. Completion | 2011-12 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00998582
The ClinicalTrials.gov registry entry for NCT00998582 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 27 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hennepin Healthcare Research Institute, which has 63 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Tenofovir disoproxil is the first listed.
NCT00998582 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00998582 about?
NCT00998582 is a clinical study titled "Artery Elasticity After Switch From Epzicom to Truvada". Recent research as suggested that use of the HIV medication abacavir (Ziagen, or co-formulated with lamivudine as Epzicom) may increase risk for heart disease, though findings from multiple studies have been inconsistent. This pilot study will examine vascular function, a marker of heart disease ris...
What is the current status of trial NCT00998582?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 27 participants. The study started on 2009-10. Estimated completion is 2011-12.
What interventions are being tested in trial NCT00998582?
The interventions under investigation include: Tenofovir disoproxil (DRUG).
Who is sponsoring clinical trial NCT00998582?
This trial is sponsored by Hennepin Healthcare Research Institute, which has 63 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.